Scott A. Barman
Research Subjects
Scott A. Barman has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Shu Zhu
Dept. of Pharmacology and Toxicology, Medical College of Georgia, Augusta, GA 30912, USA
4 shared publicationsRichard E. White
Department of 1Pharmacology and Toxicology, Medical College of Georgia, Augusta, Georgia
3 shared publicationsAlexander Brunelle
1 shared publicationArlin B. Blood
1 shared publicationCarla Blum-Johnston
1 shared publicationChelsea Wee
1 shared publication
Latest Publications
- 1 October 2009
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 297 (4) , L758-L766
Mutation of protein kinase C phosphorylation site S1076 on α-subunits affects BKCachannel activity in HEK-293 cells
Large conductance, calcium- and voltage-activated potassium (BKCa) channels are important modulators of pulmonary vascular smooth muscle membrane potential, and phosphorylation of BKCachannels by protein kinases regulates pulmonary arterial smooth muscle function. However, little is known about the effect of phosphorylating specific channel subunits on BKCachannel activity. The present study was done to determine the effect of mutating protein kinase C (PKC) phosphorylation site serine 1076 (S1076) on transfected human BKCachannel α-subunits in human embryonic kidney (HEK-293) cells, a heterologous expression system devoid of endogenous BKCachannels. Results showed that mutating S1076 altered the effect of PKC activation on BKCachannels in HEK-293 cells. Specifically, the phospho-deficient mutation BKCa-α(S1076A)/β1attenuated the excitatory effect of the PKC activator phorbol myristate acetate (PMA) on BKCachannels, whereas the phospho-mimetic mutation BKCa-α(S1076E)/β1increased the excitatory effect of PMA on BKCachannels. In addition, the phospho-null mutation S1076A blocked the activating effect of cGMP-dependent protein kinase G (PKG) on BKCachannels. Collectively, these results suggest that specific putative PKC phosphorylation site(s) on human BKCachannel α-subunits influences BKCachannel activity, which may subsequently alter pulmonary vascular smooth muscle function and tone.
- 1 October 2009
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 297 (4) , L758-L766
Mutation of protein kinase C phosphorylation site S1076 on α-subunits affects BKCachannel activity in HEK-293 cells
Large conductance, calcium- and voltage-activated potassium (BKCa) channels are important modulators of pulmonary vascular smooth muscle membrane potential, and phosphorylation of BKCachannels by protein kinases regulates pulmonary arterial smooth muscle function. However, little is known about the effect of phosphorylating specific channel subunits on BKCachannel activity. The present study was done to determine the effect of mutating protein kinase C (PKC) phosphorylation site serine 1076 (S1076) on transfected human BKCachannel α-subunits in human embryonic kidney (HEK-293) cells, a heterologous expression system devoid of endogenous BKCachannels. Results showed that mutating S1076 altered the effect of PKC activation on BKCachannels in HEK-293 cells. Specifically, the phospho-deficient mutation BKCa-α(S1076A)/β1attenuated the excitatory effect of the PKC activator phorbol myristate acetate (PMA) on BKCachannels, whereas the phospho-mimetic mutation BKCa-α(S1076E)/β1increased the excitatory effect of PMA on BKCachannels. In addition, the phospho-null mutation S1076A blocked the activating effect of cGMP-dependent protein kinase G (PKG) on BKCachannels. Collectively, these results suggest that specific putative PKC phosphorylation site(s) on human BKCachannel α-subunits influences BKCachannel activity, which may subsequently alter pulmonary vascular smooth muscle function and tone.
- Open Access
- 1 August 2009
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. 5, 663-71
RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension
Peer reviewed article authored by (Scott A Barman, Shu Zhu, Richard E White). Read article or submit your manuscript for publishing.
- 1 August 2009
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. 5, 663-71
Open AccessRhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension
Peer reviewed article authored by (Scott A Barman, Shu Zhu, Richard E White). Read article or submit your manuscript for publishing.
- Open Access
- 1 June 2008
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 2 (3) , 119-127
Original Research: Role of phosphodiesterases in modulation of BKCachannels in hypertensive pulmonary arterial smooth muscle
BKCachannels regulate pulmonary arterial pressure, and protein kinase C (PKC) inhibits BKCachannels, but little is known about PKC-mediated modulation of BKCachannel activity in pulmonary arterial smooth muscle. Studies were carried out to determine mechanisms of PKC modulation of BKCachannel activity in pulmonary arterial smooth muscle cells (PASMC) of the fawn-hooded rat (FHR), an animal model of pulmonary hypertension. Forskolin opened BKCachannels in FHR PASMC, which was blocked by PKC activation, and reversed by the phosphodiesterase (PDE) inhibitors IBMX, milrinone, and zaprinast. PDE inhibition also blocked the vasoconstrictor response to PKC activation in FHR pulmonary arteries. These results indicate that PKC inhibits cAMP-induced activation of BKCachannels and causes pulmonary vasoconstriction in hypertensive pulmonary arterial smooth muscle via PDE, which further suggests PDE inhibitors for treatment of pulmonary hypertension.
- 1 June 2008
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 2 (3) , 119-127
Open AccessOriginal Research: Role of phosphodiesterases in modulation of BKCachannels in hypertensive pulmonary arterial smooth muscle
BKCachannels regulate pulmonary arterial pressure, and protein kinase C (PKC) inhibits BKCachannels, but little is known about PKC-mediated modulation of BKCachannel activity in pulmonary arterial smooth muscle. Studies were carried out to determine mechanisms of PKC modulation of BKCachannel activity in pulmonary arterial smooth muscle cells (PASMC) of the fawn-hooded rat (FHR), an animal model of pulmonary hypertension. Forskolin opened BKCachannels in FHR PASMC, which was blocked by PKC activation, and reversed by the phosphodiesterase (PDE) inhibitors IBMX, milrinone, and zaprinast. PDE inhibition also blocked the vasoconstrictor response to PKC activation in FHR pulmonary arteries. These results indicate that PKC inhibits cAMP-induced activation of BKCachannels and causes pulmonary vasoconstriction in hypertensive pulmonary arterial smooth muscle via PDE, which further suggests PDE inhibitors for treatment of pulmonary hypertension.
- Open Access
- 1 August 2007
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 293 (2) , L472-L479
Vasoconstrictor effect of endothelin-1 on hypertensive pulmonary arterial smooth muscle involves Rho-kinase and protein kinase C
Although one of the common characteristics of pulmonary hypertension is abnormal sustained vasoconstriction, the signaling pathways that mediate this heightened pulmonary vascular response are still not well defined. Protein kinase C (PKC) and Rho-kinase are regulators of smooth muscle contraction induced by G protein-coupled receptor agonists including endothelin-1 (ET-1), which has been implicated as a signaling pathway in pulmonary hypertension. Toward this end, it was hypothesized that both Rho-kinase and PKC mediate the pulmonary vascular response to ET-1 in hypertensive pulmonary arterial smooth muscle, and therefore, the purpose of this study was to determine the role of PKC and Rho-kinase signaling in ET-1-induced vasoconstriction in both normotensive (Sprague-Dawley) and hypertensive (Fawn-Hooded) rat pulmonary arterial smooth muscle. Results indicate that ET-1 caused greater vasoconstriction in hypertensive pulmonary arteries compared with the normal vessels, and treatment with the PKC antagonists chelerythrine, rottlerin, and Gö 6983 inhibited the vasoconstrictor response to ET-1 in the hypertensive vessels. In addition, the specific Rho-kinase inhibitor Y-27632 significantly attenuated the effect of ET-1 in both normotensive and hypertensive phenotypes, with greater inhibition occurring in the hypertensive arteries. Furthermore, Western blot analysis revealed that ET-1 increased RhoA expression in both normotensive and hypertensive pulmonary arteries, with expression being greater in the hypertensive state. These results suggest that both PKC and Rho/Rho-kinase mediate the heightened pulmonary vascular response to ET-1 in hypertensive pulmonary arterial smooth muscle.
- 1 August 2007
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 293 (2) , L472-L479
Open AccessVasoconstrictor effect of endothelin-1 on hypertensive pulmonary arterial smooth muscle involves Rho-kinase and protein kinase C
Although one of the common characteristics of pulmonary hypertension is abnormal sustained vasoconstriction, the signaling pathways that mediate this heightened pulmonary vascular response are still not well defined. Protein kinase C (PKC) and Rho-kinase are regulators of smooth muscle contraction induced by G protein-coupled receptor agonists including endothelin-1 (ET-1), which has been implicated as a signaling pathway in pulmonary hypertension. Toward this end, it was hypothesized that both Rho-kinase and PKC mediate the pulmonary vascular response to ET-1 in hypertensive pulmonary arterial smooth muscle, and therefore, the purpose of this study was to determine the role of PKC and Rho-kinase signaling in ET-1-induced vasoconstriction in both normotensive (Sprague-Dawley) and hypertensive (Fawn-Hooded) rat pulmonary arterial smooth muscle. Results indicate that ET-1 caused greater vasoconstriction in hypertensive pulmonary arteries compared with the normal vessels, and treatment with the PKC antagonists chelerythrine, rottlerin, and Gö 6983 inhibited the vasoconstrictor response to ET-1 in the hypertensive vessels. In addition, the specific Rho-kinase inhibitor Y-27632 significantly attenuated the effect of ET-1 in both normotensive and hypertensive phenotypes, with greater inhibition occurring in the hypertensive arteries. Furthermore, Western blot analysis revealed that ET-1 increased RhoA expression in both normotensive and hypertensive pulmonary arteries, with expression being greater in the hypertensive state. These results suggest that both PKC and Rho/Rho-kinase mediate the heightened pulmonary vascular response to ET-1 in hypertensive pulmonary arterial smooth muscle.
- 1 April 2006
- Published by Springer Nature in Lung
- Vol. 184 (2) , 89-97
Effect of PKC Isozyme Inhibition on Forskolin-Induced Activation of BKCa Channels in Rat Pulmonary Arterial Smooth Muscle
- 1 April 2006
- Published by Springer Nature in Lung
- Vol. 184 (2) , 89-97
Effect of PKC Isozyme Inhibition on Forskolin-Induced Activation of BKCa Channels in Rat Pulmonary Arterial Smooth Muscle